Presentation is loading. Please wait.

Presentation is loading. Please wait.

Role of RHC during Hemodynamic Support in CGS

Published byLeslie Bailey Modified over 6 years ago

Similar presentations

Presentation on theme: "Role of RHC during Hemodynamic Support in CGS"— Presentation transcript:

1 Role of RHC during Hemodynamic Support in CGS
Should every MCS patient have a RHC? Role of RHC during Hemodynamic Support in CGS Daniel Burkhoff MD PhD Director, CHF, Hemodynamics and MCS Research Cardiovascular Research Foundation Adjunct Associate Professor of Medicine Columbia University

2 Disclosure Statement of Financial Interest
Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Grant/Research Support Consulting Fees/Honoraria Abiomed Heartware/Medtronic

3 Role of RHC during Hemodynamic Support in CGS
Should every MCS patient have a RHC? Role of RHC during Hemodynamic Support in CGS When the indication for MCS is hemodynamic compromise, the answer is: Most likely YES

4 PAC Measurements mVO2 Sat CO / CI PVR SVR CPO PAPi DO2 RA / CVP RV PA
PA Occlusion

5 Physiological Rationale for Use
6/12/2018 Physiological Rationale for Use Clinical evaluation may be misleading especially in unstable patients with rapidly changing hemodynamics1 Pulmonary Artery Catheters (PAC) allow for bedside measurement of major determinants of cardiac performance (preload, afterload, CO) supplying additional data for clinical decision making2 Connors AF et al., NEJM 1983 Gorlin R et al., NEJM 1977

6 Objectives of Use Diagnosis: Guide Therapy:
6/12/2018 Objectives of Use Diagnosis: Assess fluid status Assess adequacy of oxygen delivery (CI, CPI) Assess pulmonary vascular Guide Therapy: Diuretics / Fluid administration Inotropes Vasodilators / Pressors VAD Settings Provide prognostic information

7 6/12/2018 PAC Under Fire !! Despite all of the advantages of the PAC, multiple studies have shown no benefit or an increased risk of morbidity or mortality associated with its use. An intense assessment of its application in non-acute and non-shock decompensated heart failure has been provided by the ESCAPE trial1, that showed an overall neutral impact of PAC therapy over therapy guided by clinical evaluation and judgment alone. Prior results DO NOT apply to cardiogenic shock and DEFINITELY NOT in the setting of MCS2-4 Binanay C et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA Oct 5;294(13): Cohen MG et al. Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. Am J Med May;118(5):482-8 Zion MM, et al. Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT Registry. Chest. 1990;98:1331–1335. Connors AF et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA. 1996;276:889–897

8

9 Trottier and Taylor. New Horiz 1997;5:201-206
Physicians’ attitudes toward and knowledge of the pulmonary artery catheter: Society of Critical Care Medicine membership survey. Trottier and Taylor. New Horiz 1997;5: 33% of respondents incorrectly identified PA occlusion pressure on a clear tracing

10 Recent studies highlighting usefulness of RHC in heart failure and MCS

11 JACC Heart Fail. 2016 Mar;4(3):208-17.
34 STABLE, Out-patient LVAD Patients 13 HVAD (avg 2700 rpm) 21 HMII (avg 9200 rpm) Average ~57 yo Average ~500 days after implant ALL seemingly well compensated Parameters Measured: RHC 2D/3D Echocardiography

12 RPM-Dependence of PCWP
Despite appearing well compensated, many patients have very high PCWP HVAD HMII Step 0: rpms 1 Step: rpms HVAD HMII

13 Despite appearing well compensated, many patients have very high CVP
RPM-Dependence of CVP Despite appearing well compensated, many patients have very high CVP HVAD HMII Step 0: rpms 1 Step: rpms HVAD HMII

14 JACC Heart Fail. 2016 Mar;4(3):208-17.
Conclusion In patients supported by durable MCS, it is typically not possible to assess fluid status based on clinical evaluation and judgment

15 PAC Use during acute MCS
Currently available data and guidelines are inadequate to address the need for PAC use during MCS Guidelines should address: When to use PAC How to use the information derived from PAC In absence of society-endorsed guidelines, sound physiological reasoning prevails

16

17 Example: Patients on ECMO
Pressure-Volume ↑ Afterload ↑ Preload AoP and LVP ↑ AoP ↑ LVP

18 OPTIMAL MANAGEMENT REQUIRES KNOWLEDGE OF PCWP
Patient on ECMO PCWP rises substantially in many patients on ECMO Waiting for appearance of pulmonary edema on CXR can significantly delay delivery of appropriate therapy and contribute to additional morbidity Earlier recognition of need to unload the LV may increase rates of recovery Even in the absence of pulmonary edema, ECMO does not unload the LV To the degree that LV unloading contributes to recovery, PAC can expedite adjustment of therapy OPTIMAL MANAGEMENT REQUIRES KNOWLEDGE OF PCWP

19 ECMO + Impella (ECPELLA)
↑ Afterload ↑ Preload AoP LVP

20 Two Patients with Similar Clinical Presentations and Responses to IMPELLA
HR 110 ABP: ~70/45 CVP ~10 Lactate elevated (~4 mEq/L) Failure of inotropic therapy IMPELLA CP implanted Good position confirmed Flow initially good Low flow/suction alarms start

21 RHF due to RV Dysfunction
Two Patients with Similar Clinical Presentations and Responses to IMPELLA Patient 1 Patient 2 CVP 18 mmHg PA 57/30 (39) mmHg PCWP 20 mmHg CO 2.5 L/min PVR 7.6 Wood PAPi 0.95 CVP 15 mmHg PA 20/9 (12) mmHg PCWP 5 mmHg CO 2.5 L/min PVR 2.8 Wood PAPi RHF due to elevated PVR  Vasodilator therapy RHF due to RV Dysfunction  RVAD

22 PAC Use during MCS What about “wait and see how things go” approach?

23 RHC-guided Stepwise Treatment
CVP – PCWP Diagram CI <2.2 ≥2.2 1. Impella CP 3. Diuresis 2. Impella RP

24 Summary and Conclusions
Retrospective and randomized studies show no significant harm or benefit of indiscriminant PAC use during circulatory shock in ICU settings No study has evaluated the use of PAC-specific data to drive a treatment protocol known to improve outcomes Prior studies question consistent education in the interpretation of PAC tracings Knowledge of whether the tracing reliably measures intended pressures and flows is critical to success No study has ever evaluated the utility of PAC in patients receiving MCS for CGS At least one recent study shows limitation of clinical assessment of volume status in stable patients undergoing long-term MCS No specific guidelines

25 Summary and Conclusions
Use of PAC in acute pLVAD – CGS patient my hasten proper diagnosis and guide choice of therapy time is critical in CGS Use of PAC may guide optimization of therapy, particularly during MCS, to restore normal hemodynamics and physiology Fluid status (CVP, PCWP, Hb oxygenation in lungs) PVR Early detection of RHF and early intervention Use of PAC may aid during weaning process Hemodynamics are even more complex during ECMO and Biventricular support Extra care during prolonged PAC use: Infection Bleeding Thrombus Vascular damage Arrhythmias Etc..

Download ppt "Role of RHC during Hemodynamic Support in CGS"

Similar presentations

Pediatric Septic Shock

Pediatric Septic Shock
Hemodynamic Monitoring

Hemodynamic Monitoring
The golden hour(s) for severe sepsis and septic shock treatment

The golden hour(s) for severe sepsis and septic shock treatment
Mohammed Almansori MBBS, FRCPC Assistant Professor of Medicine & Interventional Cardiologist University of Dammam ECHO CLUB INVASIVE HEMODYNAMIC EVALUATION.

Mohammed Almansori MBBS, FRCPC Assistant Professor of Medicine & Interventional Cardiologist University of Dammam ECHO CLUB INVASIVE HEMODYNAMIC EVALUATION.
Weaning failure of cardiac origin

Weaning failure of cardiac origin
Pablo M. Bedano M.D. Community Regional Cancer Care.

Pablo M. Bedano M.D. Community Regional Cancer Care.
Severe Sepsis Initial recognition and resuscitation

Severe Sepsis Initial recognition and resuscitation
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.

1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Cardiogenic Shock and Hemodynamics. Outline Overview of shock – Hemodynamic Parameters – PA catheter, complications – Differentiating Types of Shock Cardiogenic.

Cardiogenic Shock and Hemodynamics. Outline Overview of shock – Hemodynamic Parameters – PA catheter, complications – Differentiating Types of Shock Cardiogenic.
Pressure, Flow, and Resistance Understanding the relationship among pressure, flow and resistance can help you understand how cardiac output and vascular.

Pressure, Flow, and Resistance Understanding the relationship among pressure, flow and resistance can help you understand how cardiac output and vascular.
Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.

Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.
SEPSIS Early recognition and management. Aims of the talk Understand the definition of sepsis and severe sepsis Understand the clinical significance of.

SEPSIS Early recognition and management. Aims of the talk Understand the definition of sepsis and severe sepsis Understand the clinical significance of.
Hemodynamic Monitoring By Nancy Jenkins RN,MSN. What is Hemodynamic Monitoring? It is measuring the pressures in the heart.

Hemodynamic Monitoring By Nancy Jenkins RN,MSN. What is Hemodynamic Monitoring? It is measuring the pressures in the heart.
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering,

Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering,
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Quality of care, part 3: bypass surgery Kim A Eagle MD Albion Walter Hewlett Professor of Internal Medicine Chief, Clinical Cardiology Co-Director, Heart.

Quality of care, part 3: bypass surgery Kim A Eagle MD Albion Walter Hewlett Professor of Internal Medicine Chief, Clinical Cardiology Co-Director, Heart.
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.

Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Monitoring Fluid Responsiveness Murat Sungur, MD Erciyes University Medical School Department of Medicine Division of Critical Care Medicine.

Monitoring Fluid Responsiveness Murat Sungur, MD Erciyes University Medical School Department of Medicine Division of Critical Care Medicine.
CPC -5 Clinical Discussion Steven R. Jones, MD. Central Features of History HL - chest radiotherapy Premature CAD dysplipidemia, otherwise limited CV.

CPC -5 Clinical Discussion Steven R. Jones, MD. Central Features of History HL - chest radiotherapy Premature CAD dysplipidemia, otherwise limited CV.
Monthly Journal article review: Vimmi Kang PGY 2

Monthly Journal article review: Vimmi Kang PGY 2

Similar presentations

Ads by Google